Dupilumab side effect in a patient with atopic dermatitis: a case report study

Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi ArabiaAbst...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Albader SS, Alharbi AA, Alenezi RF, Alsaif FM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/c8e5c67d63544b7c94d0155032748adc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c8e5c67d63544b7c94d0155032748adc
record_format dspace
spelling oai:doaj.org-article:c8e5c67d63544b7c94d0155032748adc2021-12-02T03:37:38ZDupilumab side effect in a patient with atopic dermatitis: a case report study1177-5491https://doaj.org/article/c8e5c67d63544b7c94d0155032748adc2019-05-01T00:00:00Zhttps://www.dovepress.com/dupilumab-side-effect-in-a-patient-with-atopic-dermatitis-a-case-repor-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi ArabiaAbstract: Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.Keywords: atopic dermatitis, dupilumab, eczema, adverse effectAlbader SSAlharbi AAAlenezi RFAlsaif FMDove Medical PressarticleAtopic dermatitisDupilumabMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 79-82 (2019)
institution DOAJ
collection DOAJ
language EN
topic Atopic dermatitis
Dupilumab
Medicine (General)
R5-920
spellingShingle Atopic dermatitis
Dupilumab
Medicine (General)
R5-920
Albader SS
Alharbi AA
Alenezi RF
Alsaif FM
Dupilumab side effect in a patient with atopic dermatitis: a case report study
description Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi ArabiaAbstract: Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.Keywords: atopic dermatitis, dupilumab, eczema, adverse effect
format article
author Albader SS
Alharbi AA
Alenezi RF
Alsaif FM
author_facet Albader SS
Alharbi AA
Alenezi RF
Alsaif FM
author_sort Albader SS
title Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_short Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_full Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_fullStr Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_full_unstemmed Dupilumab side effect in a patient with atopic dermatitis: a case report study
title_sort dupilumab side effect in a patient with atopic dermatitis: a case report study
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/c8e5c67d63544b7c94d0155032748adc
work_keys_str_mv AT albaderss dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy
AT alharbiaa dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy
AT alenezirf dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy
AT alsaiffm dupilumabsideeffectinapatientwithatopicdermatitisacasereportstudy
_version_ 1718401698020458496